These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 10971520)
1. Up-regulation of the tumour-associated marker CD44V6 in experimental kidney disease. Takazoe K; Foti R; Tesch GH; Hurst LA; Lan HY; Atkins RC; Nikolic-Paterson DJ Clin Exp Immunol; 2000 Sep; 121(3):523-32. PubMed ID: 10971520 [TBL] [Abstract][Full Text] [Related]
2. CD44 and hyaluronan expression in the development of experimental crescentic glomerulonephritis. Jun Z; Hill PA; Lan HY; Foti R; Mu W; Atkins RC; Nikolic-Paterson DJ Clin Exp Immunol; 1997 Apr; 108(1):69-77. PubMed ID: 9097914 [TBL] [Abstract][Full Text] [Related]
3. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Kuncová J; Kostrouch Z; Viale M; Revoltella R; Mandys V Folia Biol (Praha); 2005; 51(1):3-11. PubMed ID: 15783086 [TBL] [Abstract][Full Text] [Related]
4. CD44 variant exons in leukemia and lymphoma. Akisik E; Bavbek S; Dalay N Pathol Oncol Res; 2002; 8(1):36-40. PubMed ID: 11994761 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890 [TBL] [Abstract][Full Text] [Related]
6. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Isbel NM; Hill PA; Foti R; Mu W; Hurst LA; Stambe C; Lan HY; Atkins RC; Nikolic-Paterson DJ Kidney Int; 2001 Aug; 60(2):614-25. PubMed ID: 11473644 [TBL] [Abstract][Full Text] [Related]
7. Transient expression of CD44 variant isoforms in the ontogeny of the rat: ectoderm-, endoderm- and mesoderm-derived cells express different exon combinations. Weber B; Rösel M; Arch R; Möller P; Zöller M Differentiation; 1996 Mar; 60(1):17-29. PubMed ID: 8935925 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753 [TBL] [Abstract][Full Text] [Related]
9. Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Yokota A; Ishii G; Sugaya Y; Nishimura M; Saito Y; Harigaya K Hematol Oncol; 1998 Dec; 16(4):131-41. PubMed ID: 10414233 [TBL] [Abstract][Full Text] [Related]
10. Variant expression of CD44 in preneoplastic lesions of the lung. Wimmel A; Kogan E; Ramaswamy A; Schuermann M Cancer; 2001 Sep; 92(5):1231-6. PubMed ID: 11571737 [TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 variants in osteosarcoma. Kuryu M; Ozaki T; Nishida K; Shibahara M; Kawai A; Inoue H J Cancer Res Clin Oncol; 1999 Nov; 125(11):646-52. PubMed ID: 10541973 [TBL] [Abstract][Full Text] [Related]
12. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. Liu YJ; Yan PS; Li J; Jia JF World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351 [TBL] [Abstract][Full Text] [Related]
13. CD44 expression and regulation during mammary gland development and function. Hebbard L; Steffen A; Zawadzki V; Fieber C; Howells N; Moll J; Ponta H; Hofmann M; Sleeman J J Cell Sci; 2000 Jul; 113 ( Pt 14)():2619-30. PubMed ID: 10862719 [TBL] [Abstract][Full Text] [Related]
14. Intrinsic renal cells are the major source of interleukin-1 beta synthesis in normal and diseased rat kidney. Tesch GH; Yang N; Yu H; Lan HY; Foti R; Chadban SJ; Atkins RC; Nikolic-Paterson DJ Nephrol Dial Transplant; 1997 Jun; 12(6):1109-15. PubMed ID: 9198037 [TBL] [Abstract][Full Text] [Related]
15. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552 [TBL] [Abstract][Full Text] [Related]
16. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. van Hal NL; van Dongen GA; Stigter-van Walsum M; Snow GB; Brakenhoff RH Int J Cancer; 1999 Sep; 82(6):837-45. PubMed ID: 10446451 [TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672 [TBL] [Abstract][Full Text] [Related]
18. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Khan SA; Cook AC; Kappil M; Günthert U; Chambers AF; Tuck AB; Denhardt DT Clin Exp Metastasis; 2005; 22(8):663-73. PubMed ID: 16691370 [TBL] [Abstract][Full Text] [Related]
19. SR proteins regulate V6 exon splicing of CD44 pre-mRNA. Loh TJ; Moon H; Jang HN; Liu Y; Choi N; Shen S; Williams DR; Jung DW; Zheng X; Shen H BMB Rep; 2016 Nov; 49(11):612-616. PubMed ID: 27530682 [TBL] [Abstract][Full Text] [Related]
20. CD44v6 cell surface expression is a common feature of macrophages and macrophage-like cells - implication for a natural macrophage extravasation mechanism mimicked by tumor cells. Braumüller H; Gansauge S; Ramadani M; Gansauge F FEBS Lett; 2000 Jul; 476(3):240-7. PubMed ID: 10913621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]